ARGENT BIOPHARMA LIMITED — Proxy Solicitation & Information Statement 2023

Feb 27, 2023

==> picture [245 x 45] intentionally omitted <==

28 February 2023 ASX Code: MXC LSE Code: MXC

==> picture [36 x 145] intentionally omitted <==

==> picture [36 x 350] intentionally omitted <==

Dispatch of General Meeting Documents

MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) would like to advise that it has commenced distribution of the accompanying letter to shareholders, advising them of the details of the General Meeting of shareholders to be held at 4:00pm (AWST) Thursday, 30 March 2023, at 1202 Hay Street West Perth Western Australia 6005.

Also being dispatched to shareholders today is the Notice of General Meeting for the above meeting.

--Ends--

uthorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.co.uk

UK Broker

UK Financial and Corporate Advisor UK Broker SW4 Partners Turner Pope Rupert Fane / Nilesh Patel Andy Thacker +44 7810 056 104 +44 203 657 0050 rupert@sw4partners.com / nilesh@sw4partners.com info@turnerpope.com

UK PR Advisors

Tavistock

Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceuticals company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

==> picture [32 x 18] intentionally omitted <==

Follow us through our social media channels

==> picture [18 x 18] intentionally omitted <==

==> picture [21 x 18] intentionally omitted <==

==> picture [18 x 18] intentionally omitted <==

info@mgcpharma.co.uk | mgcpharma.co.uk MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872

1 - 1

T: +61 8 6382 3390

==> picture [204 x 38] intentionally omitted <==

28 February 2023

LETTER TO SHAREHOLDERS – UPCOMING GENERAL MEETING

Dear Shareholder,

MGC Pharmaceuticals Ltd ( Company or MGC Pharma ) advises that it is convening a General Meeting of shareholders at 4:00pm (AWST) on Thursday the 30[th] of March 2023 at 1202 Hay Street, West Perth, Australia 6005.

The Company is continuing to monitor the impact of the COVID-19 virus in Western Australia and follow guidance from the Federal and State Governments. Having considered the current circumstances, the directors have made the decision that a physical meeting will be held. Accordingly, Shareholders will be able to attend the Meeting in person, subject to them complying with any Government orders relating to COVID-19 in place at the time that the meeting is held.

In accordance with the Corporations Act 2001 the Company will not be sending hard copies of the Notice of Meeting to shareholders unless a shareholder has requested a hard copy.

A copy of the Company’s Notice of Meeting released to the ASX on 28 February 2023 is available to view on the Company’s Website at https://mgcpharma.co.uk/investors/asx/announcements.

The directors strongly encourage all shareholders to lodge a directed proxy form prior to the meeting. If you have provided an email address and have elected to receive electronic communications from the Company, you will also be sent an email with a link to an electronic copy of the important meeting documents.

If you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience. Proxy votes can be lodged with the Company’s Share Registry, Computershare Investor Services Pty Ltd online by using the following options:

Online At www.investorvote.com.au By mail Share Registry – Computershare Investor Services Pty Limited, GPO Box 242, Melbourne Victoria 3001, Australia By fax 1800 783 447 (within Australia) +61 3 9473 2555 (outside Australia) By mobile Scan the QR code on your proxy form and follow the prompts Custodian Voting For Intermediary Online subscribers only (custodians) please visit www.intermediaryonline.com to submit your voting intentions

Your sincerely,

On behalf of MGC Pharmaceuticals Ltd ,

David Lim

Company Secretary

info@mgcpharma.co.uk | www.mgcpharma.co.uk

MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth WA 6005 PO Box 1976, West Perth WA 6872 T: +61 8 6382 3390

1 of 1